Home » Stocks » BCYC

Bicycle Therapeutics PLC (BCYC)

Stock Price: $31.60 USD 0.41 (1.31%)
Updated Jul 30, 2021 4:00 PM EDT - Market closed
Market Cap 760.86M
Revenue (ttm) 11.07M
Net Income (ttm) -55.88M
Shares Out 24.08M
EPS (ttm) -2.77
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 30
Last Price $31.60
Previous Close $31.19
Change ($) 0.41
Change (%) 1.31%
Day's Open 31.20
Day's Range 30.15 - 32.25
Day's Volume 66,429
52-Week Range 15.25 - 36.99

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Bicycle Therapeutics PLC Sponsored ADR (BCYC) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stoc...

1 week ago - Zacks Investment Research

Ionis (IONS) signs a deal with Bicycle Therapeutics to incorporate the latter's optimized Bicycle peptides into its LICA delivery platform.

Other stocks mentioned: IONS
2 weeks ago - Zacks Investment Research

Bicycle Therapeutics plc (NASDAQ: BCYC) announced that Ionis Pharmaceuticals Inc (NASDAQ: IONS) has exercised its option and entered into an exclusive worldwide license and collaboration agreement to de...

Other stocks mentioned: IONS
2 weeks ago - Benzinga

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic...

2 weeks ago - Business Wire

CARLSBAD, Calif., July 13, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced that it has entered into an exclusive licensing agreement with Bicycle Therapeutics plc (NASDAQ...

Other stocks mentioned: IONS
2 weeks ago - PRNewsWire

Bicycle Therapeutics PLC Sponsored ADR (BCYC) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several sto...

3 weeks ago - Zacks Investment Research

CAMBRIDGE, England, & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicycli...

1 month ago - Business Wire

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic...

2 months ago - Business Wire

CAMBRIDGE, England, & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicycli...

2 months ago - Business Wire

Leuven, BE, Boston, MA, US – April 13th, 2021 – 7.30 AM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard-of-care ophthalmic therapies, with a c...

3 months ago - GlobeNewsWire

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic...

3 months ago - Business Wire

Bicycle Therapeutics PLC Sponsored ADR (BCYC) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving...

3 months ago - Zacks Investment Research

Oxurion is a leader in the development of pan-RGD integrin antagonists for retinal vascular disorders - THR-687 on track to enter Phase 2 development by mid-year

3 months ago - GlobeNewsWire

Leuven, BE, Boston, MA, US – April 6, 2021 – 7.30 AM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard-of-care back of the eye therapies, today ...

3 months ago - GlobeNewsWire

Leuven, BE, Boston, MA, US – March 31st, 2021 – 07.30 AM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard-of-care ophthalmic therapies, today a...

4 months ago - GlobeNewsWire

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic...

4 months ago - Business Wire

CAMBRIDGE, England, & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicycli...

4 months ago - Business Wire

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic...

4 months ago - Business Wire

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic...

4 months ago - Business Wire

Leuven, BE, Boston, MA, US – March 8, 2021 – 08.00 AM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard-of-care ophthalmic therapies, with a cli...

4 months ago - GlobeNewsWire

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ:BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic ...

6 months ago - Business Wire

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic...

6 months ago - Business Wire

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic...

8 months ago - Business Wire

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ:BCYC), a clinical-stage biotechnology company pioneering a new and differentiated class of therapeutics based on its propri...

8 months ago - Business Wire

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic...

8 months ago - Business Wire

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (Nasdaq: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic...

8 months ago - Business Wire

CAMBRIDGE, England, & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ:BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic...

8 months ago - Business Wire

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (Nasdaq: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic...

9 months ago - Business Wire

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic...

9 months ago - Business Wire

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (Nasdaq: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic...

10 months ago - Business Wire

Steven Cohen (Trades, Portfolio), head of Point72 Asset Management, disclosed this week his firm upped its stake in Bicycle Therapeutics PLC (NASDAQ:BCYC) by 175.4%.

10 months ago - GuruFocus

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic...

10 months ago - Business Wire

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic...

10 months ago - Business Wire

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic...

10 months ago - Business Wire

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic...

10 months ago - Business Wire

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic...

11 months ago - Business Wire

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic...

11 months ago - Business Wire

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic...

11 months ago - Business Wire

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ:BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic ...

11 months ago - Business Wire

Bicycle Therapeutics (BCYC) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

1 year ago - Zacks Investment Research

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic...

1 year ago - Business Wire

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic...

1 year ago - Business Wire

This biotech company was founded by a Nobel laureate.

1 year ago - The Motley Fool

Clinical trial successes could send shares of these drugmakers screaming higher.

Other stocks mentioned: BTAI, IGMS
1 year ago - The Motley Fool

Bicycle Therapeutics has been struggling lately, but the selling pressure may be coming to an end soon.

1 year ago - Zacks Investment Research

Is (BCYC) Outperforming Other Medical Stocks This Year?

1 year ago - Zacks Investment Research

These five biotech stocks could post life-changing gains for early-bird investors.

Other stocks mentioned: CPRX, FOLD, INO, NVAX
1 year ago - The Motley Fool

Top Ranked Momentum Stocks to Buy for March 16th

Other stocks mentioned: CODX
1 year ago - Zacks Investment Research

Bicycle Therapeutics PLC Sponsored ADR (BCYC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the nea...

1 year ago - Zacks Investment Research

Is (BCYC) Outperforming Other Medical Stocks This Year?

1 year ago - Zacks Investment Research

About BCYC

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company's oncology product candidates also comprise BT5528, a BTC that is in a Phase I/IIa clinical trial targeting EphA2; BT8009, which is in preclinical studies targeting Nectin-4; and CD137, an immune c... [Read more...]

Industry
Biotechnology
IPO Date
May 23, 2019
CEO
Kevin Lee
Employees
87
Stock Exchange
NASDAQ
Ticker Symbol
BCYC
Full Company Profile

Financial Performance

In 2020, BCYC's revenue was $10.39 million, a decrease of -24.72% compared to the previous year's $13.80 million. Losses were -$51.01 million, 66.7% more than in 2019.

Financial Statements

Analyst Forecasts

According to 8 analysts, the average rating for BCYC stock is "Buy." The 12-month stock price forecast is 41.33, which is an increase of 30.79% from the latest price.

Price Target
$41.33
(30.79% upside)
Analyst Consensus: Buy